Search Results

Innovative Medicine

April 28, 2014

Johnson & Johnson Announces New Collaboration with Stop TB Partnership’s Global Drug Facility to Enhance Access to Anti-TB Compound

Innovative Medicine

April 25, 2014

VOKANAMET® (canagliflozin and immediate release metformin hydrochloride fixed dose combination) approved in the European Union for treatment of adults with type 2 diabetes [1]

Innovative Medicine

April 24, 2014

SYLVANT™ (siltuximab) Receives FDA Approval to Treat Multicentric Castleman’s Disease (MCD)

First treatment approved for patients with rare blood disorder

Innovative Medicine

April 14, 2014

Final Data from the Phase 2 COSMOS Study of Janssen’s Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)

Additional Studies Presented in Genotype 1 and Genotype 4 Hepatitis C Patient Subgroups Underscore Benefit of Simeprevir-based Treatment Regimens

Innovative Medicine

April 8, 2014

Supplemental New Drug Application for IMBRUVICA™ (ibrutinib) Submitted to the U.S. FDA

New submission based on positive Phase 3 data from the RESONATE™ trial

Innovative Medicine

April 2, 2014

Janssen Initiates Phase 3 OPTIMIST Trials of Once-Daily Simeprevir in Combination with Once-Daily Sofosbuvir for the Treatment of Genotype 1 Chronic Hepatitis C

OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin

Innovative Medicine

April 1, 2014

Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy

Research

March 31, 2014

Janssen Expands the EXPLORER Global Cardiovascular Research Program with Three New Studies Evaluating XARELTO® in Patients at Risk for Venous Thromboembolism

Innovative Medicine

March 24, 2014

Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy In Treatment Of Moderate To Severe Plaque Psoriasis

Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab

Innovative Medicine

March 21, 2014

Siltuximab Receives CHMP Positive Opinion for use in the Treatment of Multicentric Castleman’s Disease, a very Rare Blood Disorder

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine